11/2/2012 9:33:35 AM
MOUNTAIN VIEW, Calif., Nov. 1, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the third quarter ended September 30, 2012.
The net loss for the three months ended September 30, 2012 was $12.6 million, compared to net income of $8.2 million during the same period in 2011. The net loss for the nine months ended September 30, 2012 was $43.8 million, compared to a net loss of $19.1 million during the same period in 2011. The financial results in 2011 were impacted positively by the recognition of a $20.0 million milestone payment received in August 2011 pursuant to a collaboration agreement with Allergan, Inc.
comments powered by